2. Academic Validation
  3. Telomerase-Targeted Cancer Immunotherapy

Telomerase-Targeted Cancer Immunotherapy

  • Int J Mol Sci. 2019 Apr 12;20(8):1823. doi: 10.3390/ijms20081823.
Eishiro Mizukoshi 1,  Shuichi Kaneko 2
Affiliations

Affiliations

  • 1 Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Ishikawa 920-8641, Japan. [email protected].
  • 2 Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Ishikawa 920-8641, Japan. [email protected].
PMID: 31013796 DOI: 10.3390/ijms20081823
Abstract

Telomerase, an Enzyme responsible for the synthesis of telomeres, is activated in many Cancer cells and is involved in the maintenance of telomeres. The activity of Telomerase allows Cancer cells to replicate and proliferate in an uncontrolled manner, to infiltrate tissue, and to metastasize to distant organs. Studies to date have examined the mechanisms involved in the survival of Cancer cells as targets for Cancer therapeutics. These efforts led to the development of Telomerase inhibitors as Anticancer drugs, drugs targeting telomere DNA, viral vectors carrying a promoter for human telomerase Reverse Transcriptase (hTERT) genome, and immunotherapy targeting hTERT. Among these novel therapeutics, this review focuses on immunotherapy targeting hTERT and discusses the current evidence and future perspectives.

Keywords

T cell; chimeric antigen receptor; dendritic cell; hTERT; immunotherapy; peptide vaccine.

Figures
Products